Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Trastuzumab-Biosimilar'
Trastuzumab-Biosimilar published presentations and documents on DocSlides.
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
Eribulin Mesylate + Trastuzumab
by easyho
as First-Line Therapy for Locally Recurrent or . M...
Synergy Satellite Event - Biosimilars in colorectal cancer
by mia
– what's your gut feeling?. 25th Anniversary EAH...
Building a Biosimilars Pathway in the U.S.
by attentionallianz
Richard . Dolinar. , MD. Endocrinologist, Chairman...
The generic and biosimilar
by alida-meadow
perspective. Warwick Smith. Director General BGMA...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Comparison of US/EU Biosimilar
by aaron
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS
by myesha-ticknor
Dr Chris Deighton. Consultant Rheumatologist . Co...
U.S. Biosimilars: An Introduction
by calandra-battersby
Disclaimers. :. By 2016, 7 of the top 10 pharmace...
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilar Biological Products
by luanne-stotts
2016 . Clinical Investigator . Training Course. S...
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
MODULE 8. Follow-on drugs: generic, biosimilar
by alida-meadow
& non-biological similar medicinal products ....
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
ASBM Biosimilars
by phoebe-click
US Prescribers and Biosimilars Naming. Kevin Olso...
Latin American Biologics/Biosimilars Conference
by giovanna-bartolotta
Presented by . the Alliance for Safe Bioloigic . ...
Mauricio Lema Medina – Clínica de Oncología Astorga / Clínica SOMA, Medellín
by delcy
Trastuzumab-emtansine. : A . very. . nice. . poi...
Module 9: HER2-Positive and Triple-Negative BC
by unita
Percent with Patients. Number of Patients (Median)...
Her2 + Breast Cancer Laura
by ximena
Bidstrup. Mrs B is a 49 . yo. woman who attended ...
Risk of Heart Failure in Breast Cancer Patients After
by sophia2
Anthracycline. and . Trastuzumab. Treatment: A R...
Antibody–Drug Conjugates: Practical Considerations and Applications in Clinical Use
by gelbero
Sara A. Hurvitz, MD, FACP. Professor of Medicine. ...
Breast Cancer in Older Patients
by ButterflyKisses
Key Issues. Etienne GC . Brain. , MD . PhD. Instit...
Cost Impact Of Biosimiliars in Oncology
by williams
Mansoor A Khan, BS, MS, BCOP. Senior Clinical Phar...
Part B Medical Drugs Requiring StepTherapy
by natalie
Drug subject to Step Therapy BRAND NAME GENERIC NA...
Part B Medical Drugs Requiring Step
by udeline
-TherapyDrug subject to Step TherapyTry these Opti...
Module 9: HER2-Positive and
by norah
Triple-Negative Breast Cancer. Jamie Carroll, APRN...
Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings
by marina-yarberry
Management of HER2 Over-Expressed Breast Cancer i...
Neoadjuvant Target Therapy in Her-2 Positive Breast Cancer
by faustina-dinatale
Dr. . Khaled Abulkhair, PhD. Medical Oncology SCE...
William J.
by tawny-fly
Gradishar. . MD, FACP. Betsy . Bramsen. Profess...
Metastatic HER2-Positive Breast Cancer: Treatment Selection
by test
First . Line and Beyond. Moderator:. Joseph Gligo...
Fast relapsing
by danika-pritchard
patients . i.e. Patient relapses during or within...
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
Category 1: Defining Terms
by jasmine
Clue: . A biologic product with no clinically mean...
What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
INSIGHTS INTO THE MARKET
by summer
FOR INFLIXIMABTable of ContentsThe Evolving Landsc...
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
by carla
Adoption by CHMP for release for consultation24 Ma...
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS
by iamamercy
Dr.G.Hima. . Bindu. ...
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
Bio similars A Presentation
by kittie-lecroy
By. ANSHUL . SHARMA. Graduate Research Scholar. D...
Load More...
